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Abstract
Background: Skin patch test is the gold standard method in diagnosing contact allergy. Although used for more
than 100 years, the patch test procedure is performed with variability around the world. A number of factors can
influence the test results, namely the quality of reagents used, the timing of the application, the patch test series
(allergens/haptens) that have been used for testing, the appropriate interpretation of the skin reactions or the
evaluation of the patient’s benefit.
Methods: We performed an Internet –based survey with 38 questions covering the educational background of
respondents, patch test methods and interpretation. The questionnaire was distributed among all representatives of
national member societies of the World Allergy Organization (WAO), and the WAO Junior Members Group.
Results: One hundred sixty-nine completed surveys were received from 47 countries. The majority of participants
had more than 5 years of clinical practice (61 %) and routinely carried out patch tests (70 %). Both allergists and
dermatologists were responsible for carrying out the patch tests. We could observe the use of many different
guidelines regardless the geographical distribution. The use of home-made preparations was indicated by 47 % of
participants and 73 % of the respondents performed 2 or 3 readings. Most of the responders indicated having
patients with adverse reactions, including erythroderma (12 %); however, only 30 % of members completed a
consent form before conducting the patch test.
Discussion: The heterogeneity of patch test practices may be influenced by the level of awareness of clinical
guidelines, different training backgrounds, accessibility to various types of devices, the patch test series (allergens/
haptens) used for testing, type of clinical practice (public or private practice, clinical or research-based institution),
infrastructure availability, financial/commercial implications and regulations among others.
Conclusion: There is a lack of a worldwide homogeneity of patch test procedures, and this raises concerns about
the need for standardization and harmonization of this important diagnostic procedure.
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Background
Skin patch test (PT) is an essential in vivo test procedure
to confirm T-lymphocyte-mediated allergic diseases and/
or sensitization in subjects with allergic contact derma-
titis, atopic eczema, as well as food and drug allergies. It
provides evidence of sensitization and can confirm the
etiological diagnosis of a suspected type IV allergy by
reproducing a local allergic reaction on a small area,
where the diluted test substances are placed. In cases in
which contact urticarial syndrome is suspected, it is also
been used to explore direct type (urticarial) reaction by
performing 20 min reading. It is a non-invasive, rather
simple method, but the allergen selection, the proper al-
lergen concentration and the interpretation of the results
require expertise. It can be reproducible when carried
out by trained health professionals [1–4].
Although during the last decades great efforts have
been devoted to optimization and standardization of the
patch testing materials and methodology [5–19], the
value of this test depends on whether the clinical presen-
tation warrants its use, the quality of reagents used, the
timing of the application, an appropriate interpretation
of the reaction and the relevance for the patient’s
benefit.
The procedure of PT still largely resembles the original
methods described; however, a wide array of interpretations
and modifications has led to diminished comparability
when PT results are reported by different observers. This
may be influenced by different professional background
training (allergy/immunology, dermatology, pediatrician or
other), type of clinical practice (private, public, clinical or
research-based institution), accessibility to various guide-
lines and different types of devices, recommendations of
the different National Society, among others.
To better appraise the many different PT methods and
forms of interpretation in use worldwide and to contrib-
ute to the harmonization of its technique for a more ra-
tional comparison of their results, the WAO Junior
Members Group (WAO JMG) conducted a first survey
among members of WAO, and representatives respond-
ing on behalf of the national Member Societies of WAO,
and the WAO JMG.
Methods
A web-based questionnaire was constructed and circu-
lated among the members of the WAO JMG Steering
Committee (July-August 2013). The final version com-
prised a total of 38 questions covering the professional
background of respondents, PT methods and interpret-
ation of the results [1–35]. The survey used a skip logic
pattern, allowing participating physicians to avoid cer-
tain sections according to their responses in preceding
questions. The questions were presented in a fixed order
and most of them were close-ended. Most of the
questions were designed to be answered in a compulsory
manner. The survey was then beta tested by the WAO
JMG and WAO headquarters before being sent out.
The protocol was approved by the WAO Executive
Committee and Board of Directors (November 2013)
and launched by e-mail by the WAO headquarters to all
representatives of, WAO Member Societies, and mem-
bers of the WAO JMG, regardless of the specialty, affili-
ation, or nationality (December 2013). We sent out an
introduction letter containing a link (Internet address)
to the online questionnaire that was unique to each par-
ticipating member. Two reminders were sent (January
2014 and March 2014) and all the respondents were
given 90 days to reply.
The data were recorded in SPSS for Windows v.22.
Analyses of the difference in frequencies across groups
were performed with the Pearson Chi-squared test and a
p value ≤0.05 was considered significant. Cramer’s V was
used for the evaluation of the strength of statistically
significant associations.
Results
We received a total of 169 completed surveys from 47
countries of within regions of WAO member Societies:
Africa/Middle-East (AME), Asia-Pacific (AP), Europe (EU),
Latin-America (LA) and North America (NA) (Fig. 1).
Among all responders, 52 % replied as members of the
WAO JMG and 48 % on behalf of their national society,
a Member Society of WAO. (Fig. 1). Most of the partici-
pants indicated allergy (76 %) as their main specialty (ac-
cording to the respective national educational
requirements), followed by clinical immunology (8 %) and
dermatology and pediatrics (both 4 %). The majority of
participants had more than 5 years of clinical practice
(61 %) and routinely carried out PT (70 %), more than
once per week (47 %) mainly in public hospitals (Table 1
and Fig. 2).
The PT was mostly used for clinical aims (61 %), but
23 % of the responders used the procedure for both
clinical and research goals, while 3 % confine the use for
research only. Both allergists and dermatologists were
responsible for carrying out PT in different countries as
informed by 43 % responses, but in Asian-Pacific
countries the number of dermatologists performing PT
predominated (Table 2).
Although 37 % indicated the use of commercial formu-
lations, 28 % used both home-made preparations and
commercialized formulations and 19 % home-made prep-
arations exclusively (Table 2). Thirty percent of physicians
indicated having no data on home-made preparations use
in healthy controls or exposed to different substances.
The participants who repeated the PT used more often
commercial formulations (48.5 %) than home-made
(13.6 %) or both (37.9 %) (χ2 = 5.980, p = 0.05, V = 0.209).
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The most used chambers were made of plastic (30 %)
and aluminum (29 %), and geographical differences
could be appreciated, as chambers with pre-loaded aller-
gens and water-proof plaster chambers were in use mainly
in Europe (Table 2).
Of all 119 participants who routinely performed PT,
83 % used clinical guidelines. The most widely used
clinical practice guideline was the AAAAI/ACAAI 2006
Practice Parameter: Contact Dermatitis (32 %), followed
by the Skin test concentrations for systemically adminis-
tered drugs – an ENDA/EAACI Drug Allergy Interest
Group position paper (24 %), the International Contact
Dermatitis Research Group (ICDRG) 1970: criteria for
patch test reading (18 %). North American physicians use
exclusively the AAAAI/ACAAI 2006 Practice Parameter:
Contact Dermatitis. The remaining guidelines used are
summarized in Fig. 3. Professionals who routinely used
guidelines in their clinical practice were those who more
often conducted PT (87.4 vs 12.6 %, χ2 = 17.373, p < 0.0005,
V = 0.361) and more frequently performed retesting (90.5
vs 9.5 %, χ2 = 3.804, p = 0.05,V = 0.174).
Professionals who routinely carried out PT (more than
one PT per week) were those who used guidelines in the
clinical practice (90.7 vs 9.3 %, χ2 = 8.420, p = 0.004, V =
0.254) and for clinical purpose (65.1 vs 34.9 %, χ2 =
6.465, p = 0.011, V = 0.216).
The main groups of the substances tested were those in
the European Standard Battery (42 %), food (36 %) and
drugs (28 %). Occupational substances were tested more
frequently in North America, Europe and Asia-Pacific and
FDA certified allergen panel was in use mainly in North
and Latin America (Fig. 4).
As indicated in Fig. 5, physicians were responsible for
applying (61 %) and reading the PT results (78 %). How-
ever, as indicated by 16 % of repliers, the PT reading was
performed by a non-physician.
Seventy-three percent of the responders usually did 2
or 3 readings of PT. The first reading was mainly per-
formed after 2 days (54 %), but 12 % did the first reading
after 20 min of the PT application. Thirty-three percent
did the second reading after 3 days and 18 % after 4 days
of the test implementation. The third reading was per-
formed by 76 responders, mainly after a week (Fig. 6).
The majority (68 %) of responders pointed out the need


































































Fig. 1 Number of responses, list and distribution of countries that participated in the survey
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Figure 7 lists the main limitations on conducting PT.
Systemic and topical corticosteroids and immunosup-
pressants were indicated as being the main drugs able to
interfere in PT results, however, systemic and topical
anti-histamines were still reported as being limitations
for the procedure (Fig. 7). Of all 148 responders, 50
(34 %) considered age as a limitation to perform the PT.
Most of those participants pointed out “less than 5 years”
as being the lower limit of age and “more than 70 years”
as being the upper limit of age (Fig. 8).
Pruritus (72 %), exacerbation of the primary local
reactions (29 %) and erythroderma (12 %) were listed
as the main adverse reactions. The professionals who
perform more than 1 PT per week observed more
often adverse reactions than those who did less than
1 patch test per week (86.7 vs 13.3 %, χ2 = 6.416, p =
0.04, V = 0.214).
Out of 142 replies, 30 % of members asked for a con-
sent form before conducting the PT and 78 % provided
an allergen information document or an allergy passport
in case of positive result. The results of PT were
recorded into the own database by 53 % of respondents,
while 29 % stored the results into the Hospital database.
None of the respondents reported the use of an Inter-
national collaboration database.
Discussion
The WAO JMG initiative on collecting data regarding
Skin Patch Test Procedures and Interpretation is the first
international survey ever conducted in the Allergy field to
Table 1 Characteristics of survey responders
Characters of responders Regions of WAO member societies
AME
(N = 12) (%)
AP
(N = 18) (%)
EU
(N = 68) (%)
LA
(N = 63) (%)
NA
(N = 8) (%)
Groups
WAO JM (N = 88) 5 (42) 8 (45) 40 (59) 32 (51) 3 (38)
WAO member society representative (N = 81) 7 (58) 10 (55) 28 (41) 31 (68) 5 (62)
Specialty
Allergist (N = 128) 7 (58) 10 (56) 56 (82) 47 (75) 8 (100)
Clinical Immunologist (N = 14) 3 (25) 0 (0) 2 (3) 9 (13) 0 (0)
Pediatrician (N = 7) 0 (0) 2 (11) 4 (6) 1 (2) 0 (0)
Dermatologist (N = 6) 0 (0) 2 (11) 3 (5) 1 (2) 0 (0)
Other clinical specialty (N = 5) 2 (17) 2 (11) 2 (3) 5 (8) 0 (0)
Researcher (N = 3) 0 (0) 2 (11) 1 (1) 0 (0) 0 (0)
Years of practice
<1 year (N = 12) 0 (0) 0 (0) 4 (6) 5 (8) 3 (37)
1 to 5 years (N = 54) 5 (42) 5 (28) 21 (31) 22 (35) 1 (13)
5 to 10 years (N = 40) 2 (16) 3 (17) 28 (41) 5 (8) 2 (25)
>10 years (N = 63) 5 (42) 10 (55) 15 (22) 31 (49) 2 (25)
Routinely carry out PT
Yes (N = 119) 6 (50) 10 (56) 49 (72) 48 (76) 6 (75)
No (N = 50) 6 (50) 8 (37) 19 (28) 15 (24) 2 (25)
Use any guideline
Yes (N = 99/119) 6 (100) 10 (100) 40 (82) 38 (79) 5 (84)
No (N = 20/119) 0 (0) 0 (0) 9 (18) 10 (21) 16 (16)
Number of PT/week
<1/week (N = 56) 2 (17) 6 (33) 20 (29) 23 (36) 5 (63)
1–10/week (N = 79) 5 (42) 6 (33) 37 (55) 29 (46) 2 (25)
11–25/week (N = 5) 1 (4) 0 (0) 2 (3) 2 (3) 0 (0)
26–50/week (N = 3) 1 (4) 0 (0) 1 (1) 1 (2) 0 (0)
>50/week (N = 4) 0 (0) 1 (6) 0 (0) 3 (5) 0 (0)
No reply (N = 22) 3 (25) 5 (28) 8 (12) 5 (8) 1 (12)
Africa/Middle-East (AME), Asia-Pacific (AP), Europe (EU), Latin-America (LA) and North America (NA)
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Table 2 Properties of the skin patch test practice
Attitudes of the skin patch test practice Regions of WAO member societies
AME
(N = 12) (%)
AP
(N = 18) (%)
EU
(N = 68) (%)
LA
(N = 63) (%)
NA
(N = 8) (%)
Who performs PT?
Allergists (N = 63) 3 (25) 5 (28) 22 (32) 32 (51) 1 (12)
Dermatologists (N = 29) 2 (17) 9 (50) 7 (10) 10 (16) 1 (12)
Both (N = 72) 7 (58) 3 (17) 37 (54) 19 (30) 6 (76)
Nobody (N = 3) 0 (0) 1 (5) 0 (0) 2 (3) 0 (0)
Other (N = 3) 1 (8) 0 (0) 2 (3) 0 (0) 0 (0)
To whom PT is performed?
Adults (N = 45) 3 (25) 5 (28) 29 (43) 7 (11) 1 (12)
Children (N = 19) 4 (33) 0 (0) 5 (7) 9 (14) 1 (12)
Both (N = 83) 3 (25) 7 (39) 26 (38) 41 (65) 6 (76)
No reply (N = 22) 2 (17) 6 (33) 8 (12) 6 (10) 0 (0)
Formulations tested
Commercial formulations (N = 62) 3 (25) 7 (39) 26 (38) 24 (38) 4 (50)
Home-made preparations (N = 32) 2 (17) 2 (11) 6 (9) 20 (32) 0 (0)
Both (N = 48) 5 (42) 1 (5) 26 (38) 12 (19) 0 (0)
No reply (N = 31) 2 (17) 8 (44) 10 (15) 7 (11) 4 (50)
Data in healthy controls for home-made preparation?
Yes (N = 55) 3 3 28 21 0
No (N = 50) 5 7 14 20 4
Kind of chambers used
Plastic (N = 50) 5 (42) 5 (28) 23 (34) 19 (30) 1 (12)
Aluminum (N = 49) 1 (8) 2 (11) 15 (22) 30 (48) 1 (12)
Pre-loaded with allergens (N = 26) 1 (8) 2 (11) 10 (15) 5 (8) 3 (38)
On water-proof plasters (N = 14) 1 (8) 3 (17) 11 (16) 0 (0) 0 (0)
Other (N = 3) 0 (0) 0 (0) 0 (0) 2 (3) 1 (12)
No reply 4 (33) 6 (33) 9 (13) 7 (11) 2 (26)
Africa/Middle-East (AME), Asia-Pacific (AP), Europe (EU), Latin-America (LA) and North America (NA)
Fig. 2 Clinical practices of the survey responders. Africa/Middle-East (AME), Asia-Pacific (AP), Europe (EU), Latin-America (LA) and North America (NA)
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review details of this procedure. This study demonstrates
the current ubiquity of the PT use in daily clinic world-
wide and underlines a clear need for harmonization of PT
procedures.
International surveys represent one of the most feasible
methods for obtaining relevant information from profes-
sionals and the online basis can contribute to collect a
higher number of responders from all around the world in
a short period of time. Considering the period of time
spent to capture the replies, this survey was successful on
reaching a high number of professionals, both WAO JMG
and responders on behalf of the National Member Soci-
eties of WAO (Table 1), which may reflect a significant
interest in this diagnostic procedure among all generations
of different specialties. The responders performing PT in
clinical practice were mainly clinicians with more than
5 years of professional experience.
The fact that there were more respondents from EU
and AME regions may reflect the higher number of
WAO members in these regions. On the other hand, we
had no feedback from countries in which PT devices
were not commercially available at the time of the
survey, such as in the Russian Federation.
The heterogeneity of PT practice (Table 2 and Fig. 2)
and the diversity of substances tested (Fig. 4) may be in-
fluenced by the level of guidelines awareness, different
Fig. 3 Guidelines in use across the regions of WAO member Societies (more than one option per responder was permitted) Africa/Middle-East (AME),
Asia-Pacific (AP), Europe (EU), Latin-America (LA) and North America (NA)
Fig. 4 Main groups of substances used in skin patch tests worldwide (more than one response/participant permitted) Africa/Middle-East (AME),
Asia-Pacific (AP), Europe (EU), Latin-America (LA) and North America (NA)
Tanno et al. World Allergy Organization Journal  (2016) 9:8 Page 6 of 10
training backgrounds (allergy/immunology, dermatology,
pediatric), accessibility to various types of devices, type
of clinical practice (public or private practice, clinical or
research-based institution), practice infrastructure avail-
ability, financial/commercial implications, and National
regulations among others. The type of clinical practice
(public or private practice, clinical or research-based
institution) may influence in the infrastructure avail-
ability, the number of patients tested per day, the
availability of patch test series (allergens/haptens) and
in the referral patterns and, therefore, impacts in the
SPT interpretation.
The WAO position paper published in 2008, stated
the definition of Allergy as specialty when a physician
who has successfully completed both a specialized train-
ing period in allergy and immunology and a training
period in either internal medicine, or a sub-specialty of
internal medicine such as dermatology, pneumology, or
otorhinolaryngology, and/or pediatrics [36]. National
educational requirements and curricula to become an
allergist may vary from this definition. Although the
allergy specialty is considered as a sub-specialty in some
countries, in the current document we decided for
considering as “allergist”, all who completed the degree
following the above statement regardless of the previous
formation.
Although the majority (68 %) of responders pointed
out the need of the same person being responsible
for subsequent readings at the different time points,
Fig. 5 indicates that the PT is read by different types
of health professionals. Therefore, we believe that all
the professionals reading the tests may require
Fig. 6 Number and time of the skin patch test readings
Fig. 5 Who is responsible for applying and reading skin patch test in your current practice?
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specific training to avoid difficulties in interpretation
and therefore diagnostic mistakes.
The majority of participants performed two readings
of PT, however, this topic seems to be still controversial,
since 36 % indicated to conduct one or three readings
(Fig. 6). This discrepancy may be influenced by the type
of substance tested, the suspected underlying mechan-
ism (T-lymphocyte-mediated or direct type urticarial re-
action), the different professional experience and the use
of different guidelines, even though, these data underline
the deficiency of interpretation standard, which can
directly impact in the diagnosis. Besides, the lack of
studies addressing the issue of quality management/is-
sues in the field of PT with regards of training of the
reader supports the need of a good quality education
and formation actions.
Most of the responders indicated having patients with
adverse reactions, including erythroderma; however, only
30 % of members currently complete an informed con-
sent form before conducting the PT, with potential legal
Fig. 8 Age limitation to perform the skin patch test (PT)
Fig. 7 Main limitations to perform the skin patch test (PT)
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implications for the physicians. Believing that this situ-
ation has to improve, the WAO JMG may work on a
consent form to be endorsed by the Allergy Academies
to protect both professionals and patients.
The use of home-made preparations was indicated by
47 % of participants, what is expected since many sub-
stances are not available in standardized test panels. The
absence of data in healthy controls for home-made prepa-
rations (Table 2) emphasizes the lack of standardization of
these tests, which can increase the false-positive results as
well as the adverse reactions. It highlights the need of
procedure standardization and asking for a consent form.
Although our understanding of the immune system’s
functions has changed substantially over the last 20 years,
the presented data still suggest a lack of full understand-
ing of the underlying immune mechanisms of contact
dermatitis exemplified by the Fig. 7, in which systemic
and topical anti-histamines were still reported as being
limitations for the PT. In general, histamine has a lim-
ited importance in the pathophysiology of this disorder
and these drugs are mainly used to smooth the symptom
of pruritus. For this reason, scientific data don’t consider
these drugs as limitations or contra-indications for the
procedure. This data also bring up the need of imple-
menting education tools to strengthen a better informa-
tion for the new generation of health professionals
working in the field.
The most important purpose of a guideline is to establish
a statement used to determine a course of action, which is
neither biding nor enforced, but aims to streamlines par-
ticular processes according to a routine. Many guidelines
have emerged to outline medical diagnostic procedures,
such as the PT [7–19] and many different Societies are
making efforts to generate comparison data by multicentric
studies. However, taking into account the current actions of
Allergy Academies to promote the recognition of Allergy
and Clinical Immunology as a specialty and to strengthen
the awareness of allergic diseases around the world [37–
39], we believe that it is now the best moment to review
some procedures in use in the daily practice to identify gaps
in which we can work on. The results of this survey high-
light the heterogeneity of attitudes and practices on using
the PT and clearly consolidate the current lack of
standardization of PT methods universally accepted. We
could observe the use of many different guidelines regard-
less to the geographical distribution (Fig. 3), the use of
home-made preparations and different time of readings.
The present study has some limitations. We are aware
of the possibility of a selection bias within large countries/
regions, the president/chair of the WAO Member Society
may not have had ample opportunity to run the survey
through all members from different states/districts within
the consultation period, especially where practices maybe
heterogeneous and in large countries/regions. It was also
not possible to access the response rate, as we are not
aware of how many recipients got the survey email and
the proportion of e-mails bounced by the online server.
The definition concepts of some terms, such as for “ery-
throderma”, used worldwide were not accessed since it
was not the aim of the current manuscript. In the current
survey, we didn’t explore specific data such as application
time or time of readings, per specific agents.
Conclusion
We strongly believe that the results of this WAO JMG
project underline a clear need of updating the PT
procedures and attitudes and will support future actions
to standardization and, therefore, harmonization and
comparability.
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